Robeco Institutional Asset Management B.V. Has $13.67 Million Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Robeco Institutional Asset Management B.V. cut its holdings in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 17.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 115,052 shares of the company's stock after selling 23,582 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in BioNTech were worth $13,665,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BNTX. Lodestone Wealth Management LLC acquired a new stake in BioNTech in the third quarter valued at approximately $8,373,000. Caas Capital Management LP lifted its holdings in BioNTech by 145.4% in the 3rd quarter. Caas Capital Management LP now owns 17,190 shares of the company's stock valued at $2,042,000 after purchasing an additional 10,185 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in shares of BioNTech by 457.9% in the 3rd quarter. New York State Common Retirement Fund now owns 218,067 shares of the company's stock valued at $25,900,000 after purchasing an additional 178,981 shares during the last quarter. First Trust Direct Indexing L.P. acquired a new position in BioNTech during the 3rd quarter worth approximately $245,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of BioNTech by 63.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company's stock valued at $2,249,000 after acquiring an additional 7,340 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BNTX. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a report on Thursday, September 19th. Bank of America upped their target price on BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a report on Monday, September 16th. Morgan Stanley upgraded BioNTech from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $93.00 to $145.00 in a report on Tuesday, September 24th. JPMorgan Chase & Co. reduced their price objective on shares of BioNTech from $125.00 to $124.00 and set a "neutral" rating for the company in a research note on Monday. Finally, HC Wainwright raised their target price on shares of BioNTech from $113.00 to $150.00 and gave the company a "buy" rating in a research note on Monday, October 7th. Five research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $134.69.

BioNTech Price Performance

Shares of BNTX stock traded up $1.59 during trading on Thursday, hitting $108.23. The company had a trading volume of 422,300 shares, compared to its average volume of 782,441. The firm has a market capitalization of $25.73 billion, a P/E ratio of -50.78 and a beta of 0.26. BioNTech SE has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The stock's 50-day moving average price is $111.00 and its 200 day moving average price is $96.31.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same period in the prior year, the firm posted $0.73 EPS. BioNTech's quarterly revenue was up 38.9% on a year-over-year basis. Equities analysts expect that BioNTech SE will post -2.93 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.